BiotechTube

DS-8201a

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Colorectal Neoplasm

Conditions

Colorectal Neoplasm

Trial Timeline

Feb 23, 2018 → Nov 10, 2020

NCT ID
NCT03384940

About DS-8201a

DS-8201a is a phase 2 stage product being developed by Daiichi Sankyo for Colorectal Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT03384940. Target conditions include Colorectal Neoplasm.

What happened to similar drugs?

15 of 20 similar drugs in Colorectal Neoplasm were approved

Approved (15) Terminated (3) Active (4)
✅Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved
✅Cetuximab (EGFR inhibitor) + Bevacizumab + Irinotecan (CPT-11) + Oxaliplatin + Leucovorin and 5-FU + CapecitabineMerckApproved
✅5-FU based doublet chemotherapy + bevacizumabRocheApproved
✅capecitabine [Xeloda]RocheApproved
✅5-Fluorouracil + Bevacizumab + Irinotecan + OxaliplatinRocheApproved
✅Oxaliplatin + Capecitabine + Bevacizumab + Leucovorin + 5-Fluouracil + IrinotecanRocheApproved
✅CapecitabineRocheApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT04132960Phase 2Completed
NCT03368196Phase 1Completed
NCT03384940Phase 2Completed
NCT03366428Phase 1Completed
NCT03248492Phase 2Terminated

Competing Products

20 competing products in Colorectal Neoplasm

See all competitors
ProductCompanyStageHype Score
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
35
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
35
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
11
ALIMTA + OxaliplatinEli LillyPhase 2
35
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
25
Bevacizumab + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 1/2
32
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
31
FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOXChugai PharmaceuticalPhase 2/3
38
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
CPT-11 and TS-1 + CPT-11, 5-FU and l-LVDaiichi SankyoPhase 2/3
38
CPT-11 based regimensDaiichi SankyoPre-clinical
26
CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)Daiichi SankyoPhase 2
35
Tivantinib + Placebo + Cetuximab + IrinotecanDaiichi SankyoPhase 1/2
32
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3WDaiichi SankyoPhase 2
35
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
CS-1008 + irinotecanDaiichi SankyoPhase 2
27
CS-7017 + PlaceboDaiichi SankyoPhase 2
27
Patritumab DeruxtecanDaiichi SankyoPhase 2
27
CS-1008 + FOLFIRIDaiichi SankyoPhase 1
29
DS-8273a + nivolumabDaiichi SankyoPhase 1
21